Doma Perpetual Capital Management’s Pacira BioSciences PCRX Stock Holding History

Doma Perpetual Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62.8M	Hold	2,777,794	–	–	16.86%	1
2025 Q4	$71.9M	Buy	2,777,794 +76,470	+3%	+$1.82M	20.21%	1
2025 Q3	$69.6M	Buy	2,701,324 +897,255	+50%	+$22M	23.38%	1
2025 Q2	$43.1M	Hold	1,804,069	–	–	16.33%	2
2025 Q1	$44.8M	Buy	1,804,069 +56,220	+3%	+$1.35M	17.62%	1
2024 Q4	$32.9M	Hold	1,747,849	–	–	16.39%	2
2024 Q3	$26.3M	Buy	1,747,849 +747,088	+75%	+$12.8M	13.29%	5
2024 Q2	$28.6M	Buy	1,000,761 +418,321	+72%	+$11.9M	13.28%	3
2024 Q1	$17M	Buy	582,440 +396,119	+213%	+$12.2M	11.32%	3
2023 Q4	$6.29M	Buy	+186,321	New	+$5.45M	6.2%	6

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Doma Perpetual Capital Management's PCRX Position: Q1 2026 in Review

Doma Perpetual Capital Management held its Pacira BioSciences (PCRX) position steady in Q1 2026 at 2,777,794 shares worth $62.8M. The position accounts for 16.86% of the portfolio, ranked #1.

Doma Perpetual Capital Management first reported a position in PCRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $71.9M in Q4 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Doma Perpetual Capital Management held 2,777,794 shares of Pacira BioSciences worth $62.8M as of Q1 2026.
Doma Perpetual Capital Management left its Pacira BioSciences share count unchanged in Q1 2026.
Pacira BioSciences made up 16.86% of Doma Perpetual Capital Management's portfolio in Q1 2026, its #1 holding.
Doma Perpetual Capital Management first reported a position in Pacira BioSciences in Q4 2023 and has held it in 10 quarters since.
Doma Perpetual Capital Management's Pacira BioSciences position peaked at $71.9M in Q4 2025.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Doma Perpetual Capital Management's 13F filing for Q1 2026, filed 15 May 2026.